Roche Partnering Casts Wide Net To Expand Company’s Neuroscience Pipeline
Executive Summary
Roche completed 80 significant deals in 2019, neuroscience partnering head Tom Zioncheck said, many of which helped the company build its growing pipeline in neurological diseases.
You may also be interested in...
Genentech’s New NMOSD Drug Offers At-Home Treatment, Lower Cost
Enspryng (satralizumab) is the third FDA-approved drug but only at-home treatment for neuromyelitis optica spectrum disorder; significant percentage of patients are not being treated.
A Rocky First Quarter For Big Pharma Stocks
Big pharma stocks, with few exceptions, saw big declines in valuation in the quarter amid the COVID-19 stock market rollercoaster, but pharma outperformed the S&P 500, showing the industry's resiliency in a global health crisis.
Deal Watch: Bayer Teams With Nuvisan On Berlin-Based Small Molecule Research Group
Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor, EyePoint, Equinox, Allergan, Nestle, Zealand, Valeritas…